Mood disorders are frequent during old age and their prevalence increases as people
age. Owing to their severe consequences, late-life mood disorders may be regarded
as an important public health problem given their association with medical and cognitive
deficits, as well as the increased risk of dementia and suicide mortality [1]. In
spite of this evidence, the occurrence of mood disorders during aging, especially
anxiety and depression, is underestimated because these psychopathologies are qualitatively
different from those experienced by younger persons, and the symptoms experienced
by elders are commonly similar to frequent disabilities generated by senescence, i.e.
apathy, cognitive impairments and sleep disorders [2]. Fortunately, not all elderly
people develop mental disorders and some of them can even have an adaptive response
in the face of stress and adversity, which is known as resilient ability [3]. As it
is deeply described in the manuscripts included in our CN Editorial [4], evidence
suggests that a healthy lifestyle (good eating habits, moderate exercise, challenging
mental activities, social support…) has a crucial role in promoting a resilient brain
during aging.
Depression is a chronic, recurring, and serious mood disorder that affects up to 20%
of the global population. Several studies about depression have reported structural
changes such as decreased frontal lobe volumes (prefrontal, orbitofrontal and anterior
cingulate cortices), as well as decreased volumes of subcortical and limbic structures
(hippocampus, amygdala, caudate nucleus and putamen) that are critical components
of the emotional and cognitive circuitry [5]. On the other hand, regarding neuronal
mechanisms, the monoamine hypothesis of depression has dominated our knowledge about
underlying pathophysiologic basis of depression for more than half a century. This
classic theory considers that a depletion in the levels of monoamines, such as serotonin,
norepinephrine, and/or dopamine is the main neurobiological basis of this disorder.
Besides, this hypothesis seemed to be supported by the mechanism of action of antidepressants.
Nevertheless, more cellular mechanisms must be considered and, recently, glia cells
and in particular, astrocytes have shown to play a central role in brain homeostasis
due to their involvement in the supply of energy metabolites to the neurons, as well
as neurotransmitter recycling and synaptic connectivity functions [6, 7]. In view
of these findings, these cells are considered as important contributors to neuronal
dysfunction and they have shown to take part not only in neurodegenerative diseases,
but also in mood disorders [8].
Regarding depression, since astrocytes participate in the uptake, metabolism and recycling
of glutamate, it is possible that an astrocytic deficit may account for the alterations
in glutamate/GABA neurotransmission in depression. For instance, a recent study of
Fullana et al. (2019) [9] showed that the regionally selective knockdown of glutamate
uptake by astrocytes in the infralimbic cortex evokes a depressive-like phenotype
in mice along with a serotonergic hypoactivity. Apart from this alteration, impairments
in another glial functions such as deficiency in neurotrophic and angiogenic factors,
as well as reduction of number and morphological changes might be also involved in
the pathogenesis of depression [8]. As we mentioned before, depression is usually
associated with volume reductions in several key frontal-subcortical regions, but
when these brain regions were analyzed histologically in aged people, no evident reduction
of glial cells was found in the grey matter compared to younger individuals [10].
Hence, gliosis has been postulated to account for this finding suggesting that subtle
vascular or inflammatory changes may be important in late-life depression.
As Czéh and Benedetto (2013) [11] proposed in their outstanding review on this topic,
antidepressant treatment could not only affect neurons, but also activate astrocytes,
triggering them to participate in specific functions that result in the reactivation
of cortical plasticity and can lead to the readjustment of abnormal neuronal networks.
Thereby, one possibility would be to promote specific astrocyte changes which could
contribute to their therapeutic effectiveness in depression during the aging. Regarding
this, antidepressant treatments, such as fluoxetine and paroxetine, have shown to
induce a stimulatory effect on the expression levels of various trophic factors in
astrocytes (brain derived neurotrophic factor (BDNF), vascular endothelial growth
factor (VEGF), and VGF mRNA expression [12]. On the other hand, astrocytes are also
an important target for antidepressants which act on monoamine oxidase B (MAO-B),
localized almost exclusively in astrocytes. Consequently, and taking this into account,
a healthy lifestyle during aging could also promote these astrocytic changes constituting
a non-pharmacological therapeutic approach for depression. For instance, several findings
demonstrated a positive effect of physical activity on depressive-related symptoms
by increasing BDNF levels in key brain regions which promote neuronal repair [13].
In addition, a promising avenue to improve mood disorders focuses on the effects of
nutrients and dietary supplementation. Specifically, docosahexaenoic acid, the most
abundant component of the n-3 PUFAs family, induced an astrocytosis reduction occurring
with age showing that astrocytes are optimal targets of n-3 PUFA action in the brain.
Interestingly, n-3 PUFA deficiency worsens age-induced hippocampal astrocytosis and
promotes neuroinflammation [14]. Finally, the environmental enrichment paradigm, in
which social, sensorial, physical and cognitive stimulation is provided to the rodents,
has shown to be useful for studying a range of psychiatric conditions, including protective
phenotypes in depression models. In line, with this downregulation of neurotrophic
factor and decreased astrocytes was restored by this housing condition [15].
To sum up, there is promising evidence about the therapeutic potential of astrocytes
questioning the classical neurocentric point of view of heath and disease. Moreover,
modulation of astrocytic structure and function could result in an effective approach
to modify and repair impaired neuronal function. With regard to the latter, we propose
that a healthy lifestyle during our lifetime, and even throughout aging, could constitute
a good approach to induce astroglial changes involved in an antidepressant effect.